Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

5

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial dihydropteroate synthase

3

specific fungi

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1948

3

1951

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute otitis media

3

Bacillary dysentery

2

Gum infection

2

Lower urinary tract infections

2

Meningococcal meningitis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

ChEMBL

5

EPA CompTox

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

2

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

SULFONAMIDES AND TRIMETHOPRIM

2

ANTIINFECTIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Short-acting sulfonamides

2

Sulfonamides

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

Salts, Hydrates, Esters, etc.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

SULPHAMOPRINE

E7C6PMZ54M

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

SULFISOMIDINE

W03L3ODK6E

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1951

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Meningococcal meningitis

Streptococcal pharyngitis

Bacillary dysentery

Lower urinary tract infections

Sulfisomidine (INN), also known as sulphasomidine (BAN until 2003), is a sulfonamide antibacterial. It’s used in the treatment, control, prevention, and improvement of the following conditions and symptoms: Lower urinary tract infections; Meningococ...

cal meningitis; Streptococcal pharyngitis; Gum infection; Bacillary dysentery.

SULFISOXAZOLE

740T4C525W

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1948

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Acute otitis media

Sulfisoxazole is a sulfonamide antibacterial antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be...

resistant. Sulfisoxazole acetyl in combination with erythromycin ethylsuccinate is used for treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae. Sulfisoxazole acetyl is a prodrug of sulfisoxazole. Acetyl group is added to make the drug poorly water soluble, and is hydrolyzed in vivo to the active drug. Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration. Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid

SULFISOMIDINE SODIUM

296707F7DU

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1951

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Meningococcal meningitis

Streptococcal pharyngitis

Bacillary dysentery

Lower urinary tract infections

Sulfisomidine (INN), also known as sulphasomidine (BAN until 2003), is a sulfonamide antibacterial. It’s used in the treatment, control, prevention, and improvement of the following conditions and symptoms: Lower urinary tract infections; Meningococ...

cal meningitis; Streptococcal pharyngitis; Gum infection; Bacillary dysentery.

SULFISOXAZOLE SODIUM

S9RAQ862V3

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1948

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Acute otitis media

Sulfisoxazole is a sulfonamide antibacterial antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be...

resistant. Sulfisoxazole acetyl in combination with erythromycin ethylsuccinate is used for treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae. Sulfisoxazole acetyl is a prodrug of sulfisoxazole. Acetyl group is added to make the drug poorly water soluble, and is hydrolyzed in vivo to the active drug. Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration. Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid

SULFISOXAZOLE ACETYL

WBT5QH3KED

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1948

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Acute otitis media

Sulfisoxazole is a sulfonamide antibacterial antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be...

resistant. Sulfisoxazole acetyl in combination with erythromycin ethylsuccinate is used for treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae. Sulfisoxazole acetyl is a prodrug of sulfisoxazole. Acetyl group is added to make the drug poorly water soluble, and is hydrolyzed in vivo to the active drug. Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration. Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1